Angela Listì

TL;DR: The promising role of TILs as biomarkers reflecting the immune response to the tumor are discussed, describing their potential ability to predict the prognosis and clinical outcome of immunotherapy in some solid tumors.

TL;DR: PD-L1 tumor over-expression seems to be associated with higher clinical activity of anti PD-1/PD- L1 MoAbs, in pre-treated NSCLC patients, suggesting a potential role of PD-L 1 expression, IHC cut-off point 1%, as predictive biomarker for the selection of patients to treat with immune-checkpoint inhibitors.

TL;DR: The potential role of ANGPTL4 in mediating the cross talk between metabolic syndromes, such as diabetes and obesity, and cancer through regulation of its expression by PPARs is discussed.

TL;DR: Several natural and synthetic microtubule-targeting agents, which showed antitumor activity and increased efficacy in comparison to traditional drugs in various preclinical and clinical studies are reviewed.

TL;DR: The role of the PI3K/AKT/mTOR pathway in TNBC patients is investigated, by summarizing the molecular features that led to the distinction of different histotypes of TNBC and highlighting the importance of integrating biological and clinical data for the development of mTOR inhibitors in order to implement targeted therapies for T NBC patients.